Beam Therapeutics (BEAM) Change in Accured Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Change in Accured Expenses data on file, last reported at -$16.3 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 11.92% year-over-year to -$16.3 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 119.06% increase from a year earlier, with the FY2025 full-year figure at $7.7 million, up 113.32% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$16.3 million, down from $14.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for BEAM reached as high as $70.4 million in Q4 2023 and fell as low as -$24.3 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $38411.8 across 5 years, with a median of -$266000.0 in 2023.
• Across the five-year window, Change in Accured Expenses jumped 733.84% in 2023 and tumbled 7225.56% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $8.4 million in 2022, then soared by 733.84% to $70.4 million in 2023, then sank by 105.79% to -$4.1 million in 2024, then jumped by 450.87% to $14.3 million in 2025, then plunged by 213.71% to -$16.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$16.3 million in Q1 2026, $14.3 million in Q4 2025, and $2.0 million in Q3 2025.